Kinaxo Biotechnologies

Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.

As part of the deal, Kinaxo will use its PhosphoScout phosphoproteomics technology to assess drugs under development at Takeda.

The acquisition of the chemical proteomics firm allows Evotec it "to take earlier educated decisions on drug efficacy, safety, and response in patients."

Kinaxo will use it mass spectrometry-based technologies to quantitatively analyze post-translational modifications in proteins on a proteome-wide scale.

Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work.

The Japanese drug firm will use Kinaxo's Cellular Target Profiling, KinAffinity, and PhosphoScout products.

Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.

The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.

Movers & Shakers

Premium

Christian Jurinke, Jeff Protentis, Jürgen Schumacher

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.